CPMD · Cannapharmarx, Inc.
$0.00
+0.00 (+0.00%)
At close · Aug 31
View the 10-Q filed May 20, 2026
Going-concern doubt
— flagged Aug 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Substantial doubt exists as to our ability to continue as a going concern based on the fact that we do not have adequate working capital to finance our day-to-day operations.”View the 10-Q filed Aug 18, 2026
Customer concentration
— key customers 100% of revenue
Key customers — 100% of revenue (three months ended March 31, 2026)
“During the three months ended March 31, 2026, the Company recognized all of its revenue of $627,462 (2025 - $nil) from related parties being D.N.S. CANTEK 2019 LTD ("Cantek"), an Israeli limited corporation owned 100% by Koze, and for which Mr. Tal serves as a financial advisor.”
Market Cap
$1.56M
Shares
708.69M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.00
Open$0.00
Day$0.00–0.00
52W close$0.00–0.01
Avg vol 30d86K
Short int6K · 0.0% float · 1.0d
Short vol100%
DataJan 2020–Aug 2026
Filing10-Q · Aug 18
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 18, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−35%
below
Price vs 50-day avg
+9%
above
RSI (14)
57
neutral
MACD trend
Negative
52-week position
21%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+14%
trailing
6-month return
−40%
trailing
YTD return
−54%
this year
Relative strength
−53%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Fundamentals
Revenue growth
+66%
Y/Y
Gross margin
-153%
expanding
EPS growth
0%
Y/Y
Free cash flow
$-794.6K
Balance sheet
$6.2M
net debt
Quant / Vol
risk profile
Volatility
374%
annualized · 1-yr
Max drawdown
−92%
past year
ATR
16.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−35%
Bearish
Price vs 50-day avg
+9%
Bullish
RSI (14)
57
Neutral
MACD trend
Negative
Bearish
52-week position
21%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0
Now $0 · 21%
Range high $0
vs 200-day avg -35%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CPMD
this stock
Cannapharmarx, Inc.
|
$1.56M | -53.8% | +66.1% | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.58B | +15.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.38B | -0.1% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.46B | -0.8% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CPMD | +50.0% | +14.3% | -40.0% | +14.3% | -53.9% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | +49.5% | +13.1% | -53.3% | +11.6% | -66.3% |